Evidence map›Paper›PMID 39333272›Full record

ArticleScientific reports2024

Pan-cancer analysis of the immunological and oncogenic roles of ATAD2 with verification in papillary thyroid carcinoma.

Zhecheng Li, Yaxin Zhao, Peng Huang, Zhaoyi Wu, Dengjie Ouyang, Adolphus Osei Nyarko, Lei Ai, Zhejia Zhang, Shi Chang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Zhecheng Li *Department of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yaxin Zhao *Department of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Peng HuangDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhaoyi WuDepartment of Thyroid and Breast Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Human Normal University, Changsha, 410008, China.
Dengjie OuyangDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Adolphus Osei NyarkoDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Lei AiDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zhejia ZhangDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China. zhangzhejia@csu.edu.cn.
Shi ChangDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China. changshi@csu.edu.cn.

Funding

National Natural Science Foundation of China 81974423The Research and Innovation Project Foundation for Graduate in Hunan Province CX20230377
6 · The paper itself

Abstract

ATAD2 (ATPase Family AAA Domain-Containing 2) is highly expressed across varies tumor types, yet its common roles in tumor progression and immune interaction remain unclear. We analyzed the expression and alteration profiles of ATAD2, along with its diagnostic and prognostic role in pan-cancer, utilizing TCGA, GTEx, CPTAC, HPA, and cBioPortal databases. Furthermore, we examined the relationship between ATAD2 and immune infiltration utilizing single-cell sequencing data and TCGA database. Additionally, the expression and oncogenic functions of ATAD2 were verified in papillary thyroid carcinoma (PTC) through MTT, wound-healing, transwell, and flow cytometry assays. Our results revealed significant overexpression of ATAD2 in most cancers, strongly associated with poor prognosis. Amplification was the most frequent alteration type of ATAD2, with its mutation correlating with improved overall survival. ATAD2 was positively correlated with multiple inhibitory immune checkpoints and closely associated with the immunosuppressive microenvironment, particularly in PTC. In vitro experiments demonstrated that ATAD2 promoted the proliferation, migration, and invasion of PTC cells by activating the PI3K-AKT pathway and modulating the G1/S cell cycle checkpoint. Collectively, ATAD2 holds promise as a biomarker for pan-cancer diagnosis and prognosis, as well as a predictor of immunotherapeutic responsiveness and a therapeutic target to enhance the efficacy of existing anti-tumor immune therapies.

Indexed as

ATPases Associated with Diverse Cellular ActivitiesDNA-Binding ProteinsThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMutationPrognosisTumor MicroenvironmentATAD2 protein, humanATPases Associated with Diverse Cellular ActivitiesBiomarkers, TumorDNA-Binding ProteinsATAD2Pan-cancerPapillary thyroid carcinomaTherapeutic targetTumor immune microenvironment

Identifiers

PMID39333272
PMCPMC11436736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.